2.AGAIN研究 (JCOG1404/WJOG8214L) :EGFR-TKI单药对比EGFR-TKI联合顺铂+培美曲塞一线治疗EGFR突变晚期非鳞非小细胞肺癌的III期研究 A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treat...
●摘要号:LBA 9009 A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non-small-cell lung cancer (NSqNSCLC) harboring EGFR ac...
摘要号: LBA9009 A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR acti...
●摘要号:LBA 9009 A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non-small-cell lung cancer (NSqNSCLC) harboring EGFR ac...
一项比较EGFR酪氨酸激酶抑制剂(EGFR-TKI)单药治疗 vs. EGFR-TKI+顺铂(CDDP)+培美曲塞(PEM)一线治疗EGFR激活突变的晚期非鳞状NSCLC(EGFR-NSqNSCLC)的3期研究:JCOG1404/WJOG8214L、AGAIN研究 Presenter:Shintaro Kanda ● 背景 AGAIN III期研究中,对比了吉非替尼联合顺铂+培美曲塞或EGFR-TKI单药一线治疗EGFR突变非...